WHO Warns of Limited Access to Obesity Drugs as Global Rates Surge

The World Health Organization has issued its first guidance on GLP-1 weight-loss drugs, warning that fewer than 10% of people who could benefit from treatments like Wegovy can currently access them. With global obesity now affecting over one billion people—and projected to surpass two billion by 2030—WHO says high prices, restricted production, and supply shortages are major obstacles.

WHO has added GLP-1 medicines to its essential medicines list for overweight patients with diabetes and emphasises that obesity is a chronic condition requiring long-term, comprehensive care. While the drugs can significantly reduce weight, they must be paired with diet and exercise support to maintain results. Production capacity could only meet demand for about 100 million people, prompting WHO to urge expanded access, including voluntary licensing once patents expire.

GLP-1 therapies mimic natural hormones to curb appetite, but stopping treatment often leads to regained weight. Obesity contributes to millions of deaths each year.

03-12-2025